11 unknown. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 11 |
| Phase 1 | 4 | Unknown 4 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia Zanubrutinib, Bendamustine, Rituximab - Waldenström's Macroglobulinemia | Phase 2 | Unknown | Shanghai Changzheng Hospital | 60 | 2023-08-01 | 2023-09-14 |
| The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma Pomalidomide, Bendamustine, Dexamethasone - Relapsed, Refractory, Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 56 | 2021-02-01 | 2021-02-21 |
| CyBeR Association in Relapsed/Refractory DLBCL Rituximab, Bendamustine, Cytarabine - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | University Hospital, Caen | 78 | 2016-06-01 | 2016-05-04 |
| BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma Busulfan, Etoposide, Bendamustine - Lymphoma, Non-Hodgkin | Phase 2 | Unknown | Pusan National University Hospital | 20 | 2016-02-01 | 2016-07-19 |
| BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation Bendamustine - Relapsed/Refractory Malignant Lymphomas | Phase 2 | Unknown | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | 100 | 2016-01-22 | 2018-05-22 |
| CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients GA101 (Obinutuzumab), Bendamustine - Chronic Lymphocytic Leucemia | Phase 2 | Unknown | Munich Municipal Hospital | 27 | 2014-11-01 | 2018-08-13 |
| Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma Bendamustine, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Cristina Gasparetto | 56 | 2013-01-07 | 2024-02-20 |
| A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma Lenalidomide, Bendamustine, Bio-specimen Retention - Recurrent Adult Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale | 36 | 2011-07-01 | 2015-08-11 |
| Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Bendamustine, Gemcitabine, Vinorelbine - Hodgkin's Lymphoma | Phase 2 | Unknown | Armando Santoro, MD | 59 | 2011-07-01 | 2014-01-29 |
| Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma Bendamustine, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Gruppo Italiano Studio Linfomi | 60 | 2010-02-01 | 2013-04-05 |
| Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL Bendamustine, Rituximab - Lymphoma, High-Grade | Phase 2 | Unknown | University of Magdeburg | 30 | 2004-08-01 | 2006-10-06 |
Recurrence (4) · Hodgkin Disease (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (1) · Waldenstrom Macroglobulinemia (1)
Armando Santoro, MD (1) · Cristina Gasparetto (1) · Gruppo Italiano Studio Linfomi (1) · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (1) · Munich Municipal Hospital (1) · Pusan National University Hospital (1) · Shanghai Changzheng Hospital (1) · State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia (1) · Sun Yat-sen University (1) · University Hospital, Caen (1) · University of Magdeburg (1)
Italy (3) · China (2) · Germany (2) · Russia (1) · South Korea (1) · United States (1)
Antonio Pinto, MD (1) · Armando Santoro, MD (1) · Clemens-Martin Wendtner, Prof. Dr. (1) · Fortunato Morabito, MD (1) · Gaetano Corazzelli, MD (1) · Gandhi Damaj, PHD (1) · Gwynn Long, MD (1) · Hojin Shin (1) · Juan Du, Doctor (1) · Martin Mohren, PD (1) · Vladislav Sarzhevskiy, MD, PhD (1)
PMID 23753028, PMID 27382096, PMID 27442600, PMID 31935284
2015 (1)